ADXS31-164
Breast Cancer
Her/2-neu is over expressed in various cancers such as breast (40%), melanoma (30%), pancreatic (20%), ovarian (30%) & gastric (19%). Advaxis proven the efficacy of using a live Listeria vaccine for the treatment of HER2 related diseases by constructing multiple vectors that express overlapping fragments of the rat version of this molecule (about 1,000 residues). Following this work the company developed a novel vaccine based on an entirely new vaccine strain of Listeria that is more attenuated and more immunogenic than the strain currently in the clinic with ADXS11-001. By identifying and isolating the immunogenic portions of the multiple vaccines tested the company was able to create a chimeric antigen comprised of these immunogenic epitopes and fuse it to LLO to create an extremely powerful vaccine.
We have published, or publications are currently in press, that show not only does this vaccine eliminate existing tumors, but prevents metastases, can treat tumors within the brain (a difficult immune site frequently not amenable to treatment), and has even prevented the occurrence of spontaneous tumors in a year long study of transgenic animals who have had tumor causing oncogenes inserted into their DNA, and who thus get tumors spontaneously.
